Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Yi Chuan ; 42(11): 1081-1092, 2020 Nov 20.
Artigo em Chinês | MEDLINE | ID: mdl-33229315

RESUMO

Interspecific hybrid male sterility is a common occurrence in nature and plays an important role in species reproductive isolation. Dzo (cattle-yak), the offspring of interspecific cross between domestic yak (Bos grunniens) and cattle (Bos taurus), is a unique animal model for investigating interspecific hybrid male sterility. Dzo females are completely fertile while the males are sterile. In recent years, molecular studies have demonstrated that the expressions of genes were dysregulated during meiosis in Dzo testis, as compared to those in cattle or yak. Other studies have revealed that epigenetic factors/events, such as DNA methylation, histone modification and non-coding RNA, are also involved in spermatogenesis. This review summarizes the dysregulation of gene expression, DNA methylation, microRNA (miRNA), PIWI-interacting RNA (piRNA), long non-coding RNA (lncRNA), and histone methylation modification during meiosis in Dzo testis. These results highlighted the potential roles of genetic and epigenetic regulations of meiosis in Dzo testis, thereby providing a more detailed understanding on the molecular mechanisms of interspecific hybrid male sterility.


Assuntos
Epigênese Genética , Regulação da Expressão Gênica no Desenvolvimento , Infertilidade Masculina , Animais , Bovinos/genética , Infertilidade Masculina/genética , Masculino , Meiose , Espermatogênese , Testículo
2.
World J Gastroenterol ; 22(43): 9571-9585, 2016 Nov 21.
Artigo em Inglês | MEDLINE | ID: mdl-27920478

RESUMO

AIM: To determine whether diabetes mellitus (DM) affects prognosis/recurrence after liver transplantation (LT) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). METHODS: A retrospective study was conducted between January 2000 and August 2013 on 1631 patients with HBV-related HCC who underwent LT with antiviral prophylaxis. Patient data were obtained from the China Liver Transplant Registry (https://www.cltr.org/). To compare the outcomes and tumor recurrence in the HBV-related HCC patients with or without DM, statistical analyses were conducted using χ2 tests, Mann-Whitney tests, the Kaplan-Meier method, log-rank tests and multivariate step-wise Cox regression analysis. RESULTS: Univariate analysis of 1631 patients who underwent LT found overall 1-, 3- and 5-year survival rates of 79%, 73% and 71% respectively in the DM patients, and 84%, 78% and 76% in the non-DM patients respectively. Overall survival rate differences after LT between the two groups were significant (P = 0.041), but recurrence-free survival rates were not (P = 0.096). By stratified analysis, the overall survival rates in DM patients for age > 50 years (P = 0.002), the presence of vascular invasion (P = 0.096), tumors ≤ 3 cm (P = 0.047), two to three tumor nodules (P = 0.007), Child-Pugh grade B (P = 0.018), and pre-LT alanine aminotransferase levels between 40 and 80 IU/L (P = 0.017) were significantly lower than in non-DM patients. Additionally, serum α-fetoprotein level > 2000 ng/mL (P = 0.052) was associated with a significant survival difference trend between DM and non-DM patients. Multivariate analysis showed that the presence of DM (P < 0.001, HR = 1.591; 95%CI: 1.239-2.041) was an independent predictor associated with poor survival after LT. CONCLUSION: HBV-related HCC patients with DM have decreased long-term overall survival and poor LT outcomes. Prevention strategies for HCC patients with DM are recommended.


Assuntos
Carcinoma Hepatocelular/cirurgia , Diabetes Mellitus/epidemiologia , Hepatite B/epidemiologia , Neoplasias Hepáticas/cirurgia , Transplante de Fígado , Sobreviventes , Antivirais/uso terapêutico , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/virologia , Distribuição de Qui-Quadrado , China/epidemiologia , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/mortalidade , Intervalo Livre de Doença , Feminino , Hepatite B/diagnóstico , Hepatite B/mortalidade , Humanos , Estimativa de Kaplan-Meier , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/virologia , Transplante de Fígado/efeitos adversos , Transplante de Fígado/mortalidade , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Recidiva Local de Neoplasia , Modelos de Riscos Proporcionais , Sistema de Registros , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento
4.
Turk J Gastroenterol ; 26(5): 429-34, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26350690

RESUMO

BACKGROUND/AIMS: Liver transplant recipients include patients who present with almost all kinds of end-stage liver disease. Studying the relationship between gallstones and end-stage liver disease among liver transplant recipients is becoming important. MATERIALS AND METHODS: Multiple logistic regression analysis was applied to assess 1640 liver transplant recipients. Multiple factors were involved in the analysis, including age, sex, total bilirubin and total cholesterol levels, Child score, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, alcoholic cirrhosis, and hepatocellular carcinoma (HCC). RESULTS: Age and Child score are independent risk factors for the development of gallstone disease (GD). The average age of the recipients in the GD group was 49.22±9.96 years, which was significantly higher than that in the GD-free group (48.23±9.79 years). The Child score of the recipients in the GD group was 9.21±2.47, which was significantly lower than that of the recipients in the GD-free group, which was 8.79±2.48 (t=3.23, p<0.001). We also found that hepatitis B is an influential factor in GD. CONCLUSION: The prevalence of gallstones among liver transplant recipients is related to the Child score and patient age. The prevalence of GD is lower in patients with HCC and in those who are HBV positive and is relatively higher in HCV-positive patients and in those with alcoholic cirrhosis, although no significant differences were found.


Assuntos
Cálculos Biliares/epidemiologia , Transplante de Fígado/efeitos adversos , Transplantados , Adolescente , Adulto , Idoso , China/epidemiologia , Doença Hepática Terminal/cirurgia , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Fatores de Risco , Adulto Jovem
5.
BMC Cancer ; 15: 232, 2015 Apr 08.
Artigo em Inglês | MEDLINE | ID: mdl-25886479

RESUMO

BACKGROUND: Liver transplantation is a treatment option for combined hepatocellular and cholangiocellular carcinoma (cHCC-CC) but its prognostic significance remains unclear. The present study aimed to evaluate the therapeutic effects of liver transplantation on cHCC-CC and analyze the clinicopathological factors affecting prognosis. METHODS: Retrospective analysis of the clinicopathological data of a case series of 21 patients with cHCC-CC who underwent orthotopic liver transplantation from April 2000 to April 2011 was performed. Cumulative survival rate and tumor-free survival rate were calculated using the Kaplan-Meier method followed by the log-rank test. RESULTS: The operative survival rate of the 21 patients was 100%; the 30 day mortality was 4.8% (1/21) and 90-day mortality was 9.5% (2/21); 1-, 2-, 3-, and 5-year overall cumulative survival rates were 64%, 47%, 39%, and 39%, respectively; and the corresponding cumulative tumor-free survival rates were 64%, 37%, 30%, and 30%, respectively. Cumulative tumor diameter, lymph node metastasis, macroscopic portal vein tumor thrombus, and mixed states according to Allen typing were identified as the primary influencing factors of poor prognosis (all P < 0.05). CONCLUSION: Liver transplantation may be an effective therapeutic method for the treatment of cHCC-CC. Strict screening of potential liver transplantation candidates with cHCC-CC can help reduce the risks of tumor recurrence and metastasis.


Assuntos
Neoplasias dos Ductos Biliares/complicações , Neoplasias dos Ductos Biliares/terapia , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/terapia , Colangiocarcinoma/complicações , Colangiocarcinoma/terapia , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/terapia , Transplante de Fígado , Adulto , Idoso , Neoplasias dos Ductos Biliares/diagnóstico , Neoplasias dos Ductos Biliares/mortalidade , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/mortalidade , Colangiocarcinoma/diagnóstico , Colangiocarcinoma/mortalidade , Feminino , Seguimentos , Humanos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/mortalidade , Transplante de Fígado/métodos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Estudos Retrospectivos , Resultado do Tratamento
6.
Hepatobiliary Pancreat Dis Int ; 14(1): 50-5, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25655290

RESUMO

BACKGROUND: Donor shortage is the biggest obstacle in organ transplantation. Living donor liver transplantation (LDLT) has been considered as a valuable approach to shortening waiting time. The objectives of this study were to investigate the feasibility of utilizing donors older than 50 years in LDLT and to evaluate the graft function and recipient survival. METHODS: All LDLT cases (n=159) were divided into the older (donor age≥50 years, n=10) and younger (donor age<50 years, n=149) donor groups. Donor graft and recipient condition pre-, intra- and post-operation were compared between the two groups. In particular, graft functions and recipient survivals were analyzed. RESULTS: The median donor age was 58.5 (52.5-60.0) years in the older donor group and 25.0 (23.0-32.0) in the younger donor group. There was no significant difference in cold ischemic time, anhepatic phase and operation time between the older and younger donor groups (P>0.05). However, the volume of red blood cell transfused in operation was greater in the older donor group than in the younger donor group (1900 vs 1200 mL, P=0.023). The 1-, 3- and 5-year graft survival rates were 90%, 80% and 80% for the older donor group, and 92%, 87% and 87% for the younger donor group, respectively (P=0.459). The 1-, 3- and 5-year survival rates were 100%, 90% and 90% for recipients with older grafts, and 93%, 87% and 87% for those with younger grafts, respectively (P=0.811). CONCLUSION: It is safe for a LDLT recipient to receive liver from donors older than 50 years, and there is no significant adverse effect on graft function and long-term patients' survival.


Assuntos
Seleção do Doador , Sobrevivência de Enxerto , Transplante de Fígado/métodos , Doadores Vivos , Sobreviventes , Adolescente , Adulto , Fatores Etários , Idoso , Estudos de Viabilidade , Feminino , Humanos , Estimativa de Kaplan-Meier , Transplante de Fígado/efeitos adversos , Transplante de Fígado/mortalidade , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Taxa de Sobrevida , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
7.
Transpl Int ; 28(1): 89-94, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25132515

RESUMO

To improve the technique of suprahepatic vena cava (SHVC) reconstruction in rat OLT, novel magnetic rings were designed and manufactured to facilitate reconstruction of SHVC and shorten the anhepatic time. One-hundred and twenty adult male Wistar rats were randomly divided into two groups: rings group (n = 30), using magnetic rings for SHVC reconstruction; suture group (n = 30), 7/0 prolene suture was used for SHVC running anastomosis as control. Cuff techniques were used for portal vein and infrahepatic vena cava reconstruction as Kamada and Calne described. The bile duct was reconnected with a stent. The hepatic re-arterialization was omitted. In the rings group, the SHVC reconstruction took 0.91 ± 0.24 (mean ± SD) min; the anhepatic phase and the recipient operation time were 5.63 ± 0.65 min and 36.02 ± 8.02 min, respectively. In suture group, the anastomotic time of SHVC was 10.40 ± 2.11 min; the anhepatic phase and the recipient operation time were 17.76 ± 2.51 and 49.38 ± 12.06 min, respectively, and there was statistically significant difference between the two groups. The ALT levels reached peak at 24 h post-OLT (186.2 ± 32.5 IU/l) and restored to normal level at 96 h gradually. In the rings group, 29 of 30 rats survived at day 7 and 28 of 30 rats survived at day 30. In contrast, only 25 of 30 recipients in suture group remained alive at day 7 and 22 of 30 remained alive at day 30 (P < 0.05). Better anastomotic healing was founded in rings group by pathology and scanning electron microscope. The magnetic rings technique provides a novel, simple method for SHVC reconstruction of OLT in rat. It significantly shortens anhepatic phase, while the success rate of the operation is satisfactory.


Assuntos
Anastomose Cirúrgica/métodos , Transplante de Fígado , Veia Cava Inferior/fisiopatologia , Animais , Aorta/patologia , Ductos Biliares/cirurgia , Boro/química , Desenho de Equipamento , Ferro/química , Fígado/cirurgia , Magnetismo , Masculino , Microscopia Eletrônica de Varredura , Neodímio/química , Duração da Cirurgia , Distribuição Aleatória , Ratos , Ratos Wistar , Stents , Procedimentos Cirúrgicos Vasculares , Cicatrização
8.
Hepatogastroenterology ; 61(133): 1363-7, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25436312

RESUMO

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) mainly arises from underlying liver disease. Complicated liver cirrhosis and secondary hypersplenism are the most risk factors preventing surgical treatment of patients with HCC. The present study aimed at investigating the safety and long term outcome of patients with HCC and liver cirrhosis undergoing synchronous hepatectomy and splenectomy. METHODOLOGY: The clinical data of 306 cases of patients with HCC and liver cirrhosis undergoing curative hepatectomy were reviewed. 18 cases underwent synchronous hepatectomy and splenectomy. The rest 288 cases of HCC with hepatectomy only were compared in aspects of clinicopathological and surgical variables and surgical outcomes. RESULTS: Preoperative hemoglobin and platelet count were significantly lower in splenectomy than non-splenectomy group (p<0.01, respectively). Patients undergoing combined splenectomy and hepatectomy needed longer surgery time and hospital stay time, and transfused much more blood intraoperatively (p=0.07, 0.03, and 0.02), and also experienced more portal vein thrombosis (p<0.01). The level of hemoglobin and platelet increased after splenectomy and finally to normal level one month postoperatively. There was no statistical difference of overall and disease-free survival of patients in splenectomy and non-splenectomy groups (p>0.05). CONCLUSIONS: With strict selection, patients with HCC and hypersplenism could undergo combined splenectomy and hepatectomy safely.


Assuntos
Carcinoma Hepatocelular/cirurgia , Hepatectomia , Hiperesplenismo/cirurgia , Cirrose Hepática/cirurgia , Neoplasias Hepáticas/cirurgia , Esplenectomia , Carcinoma Hepatocelular/sangue , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/mortalidade , Intervalo Livre de Doença , Feminino , Hepatectomia/efeitos adversos , Hepatectomia/mortalidade , Humanos , Hiperesplenismo/sangue , Hiperesplenismo/diagnóstico , Hiperesplenismo/mortalidade , Estimativa de Kaplan-Meier , Cirrose Hepática/sangue , Cirrose Hepática/diagnóstico , Cirrose Hepática/mortalidade , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Seleção de Pacientes , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Esplenectomia/efeitos adversos , Esplenectomia/mortalidade , Taxa de Sobrevida , Fatores de Tempo , Resultado do Tratamento
9.
World J Gastroenterol ; 20(36): 13159-66, 2014 Sep 28.
Artigo em Inglês | MEDLINE | ID: mdl-25278711

RESUMO

AIM: To investigate the incidence of de novo hepatitis B virus (HBV) infection after pediatric living donor liver transplantation (LDLT) and to analyze the risk factors associated with this de novo HBV infection. METHODS: The clinical and laboratory data of children who underwent LDLT from June 2010 to September 2012 in First Center Hospital in Tianjin, China, were retrospectively included in the study. Intrahepatic HBV DNA in donors and recipients was quantified by real-time polymerase chain reaction using DNA extracted from formalin-fixed, paraffin-embedded tissues. RESULTS: Between June 2010 to September 2012, 32 consecutive pediatric patients underwent LDLT in our institute. Thirty LDLT patients (13 girls and 17 boys) were followed up for a median of 15 mo, of whom 53.3% (16/30) were hepatitis B core antibody (HBcAb) positive and 36.7% (11/30) were hepatitis B surface antibody (HBsAb)/HBcAb positive before transplantation. Sixteen of the children received HBcAb-positive allografts, and 43.7% (7/16) of the grafts were found to be intrahepatic HBV DNA positive. De novo HBV infection developed in 16.1% (5/30) of the children within a median of 11 mo after transplantation. All five of the HBV-infected children had received HBcAb-positive allografts, four of which were intrahepatic HBV DNA positive. Two of the children developed de novo HBV infection despite the preoperative presence of both HBsAb and HBcAb CONCLUSION: In pediatric recipients, positive intrahepatic HBV DNA in allografts could be a risk factor for de novo HBV infection from HBcAb-positive allografts. HBsAb/HBcAb positivity in pediatric LDLT patients before transplantation exhibited only weak effectiveness in protecting them against de novo HBV infection from HBcAb-positive allografts.


Assuntos
Infecção Hospitalar/transmissão , Hepatite B/transmissão , Transplante de Fígado/efeitos adversos , Doadores Vivos , Adulto , Fatores Etários , Aloenxertos , Pré-Escolar , China/epidemiologia , Infecção Hospitalar/diagnóstico , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/virologia , DNA Viral/análise , Feminino , Hepatite B/diagnóstico , Hepatite B/epidemiologia , Hepatite B/virologia , Anticorpos Anti-Hepatite B/sangue , Antígenos E da Hepatite B/sangue , Vírus da Hepatite B/genética , Vírus da Hepatite B/imunologia , Humanos , Incidência , Lactente , Transplante de Fígado/métodos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
10.
Pediatr Transplant ; 18(1): 58-63, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24283660

RESUMO

To identify the risk factors for new-onset seizures after pediatric LT and to assess their clinical implications and long-term prognosis. The clinical and laboratory data of 27 consecutive children who underwent LT from January 2007 to December 2010 in our center were analyzed retrospectively. Patients were divided into seizures group and a non-seizures group. Pre-operative, intra-operative, and post-operative data were collected. Seizures occurred in four children, an incidence of 14.8%. All exhibited generalized tonic-clonic seizures within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level. Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures. All children who experienced seizures survived with good graft function and remained seizure-free without anti-epileptic drugs over a mean follow-up period of 33.7 ± 14.6 months. High trough TAC level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT. High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for TAC-related seizures.


Assuntos
Imunossupressores/efeitos adversos , Transplante de Fígado , Convulsões/induzido quimicamente , Tacrolimo/efeitos adversos , Adolescente , Adulto , Fatores Etários , Criança , Pré-Escolar , Feminino , Sobrevivência de Enxerto , Humanos , Lactente , Masculino , Análise Multivariada , Período Pós-Operatório , Prognóstico , Estudos Retrospectivos , Fatores de Risco
12.
Viral Immunol ; 25(5): 368-78, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22946668

RESUMO

To provide a basis for improved prevention and treatment of hepatitis B virus (HBV) re-infection after liver transplantation, variations in the S and P genes of HBV under immunosuppression in vitro and their association with patient prognosis were investigated. For the in vitro study, HepG2.2.15 hepatocellular carcinoma cells stably producing HBV particles were treated with the immunosuppressants methylprednisolone (MP) and tacrolimus (FK506) at doses found to be non-toxic by the methylthiazolyl tetrazolium (MTT) cell viability assay. MP dose-dependently inhibited HBV DNA expression in HepG2.2.15 cells, while FK506 did not, as determined by quantitative real-time PCR (qRT-PCR). By gene sequencing, both MP and FK506 were found to cause variations in HBV S, P, and S/P overlapping regions. MP- but not FK506-induced mutations were common in the glucocorticoid response element of the P region, while both immunosuppressants caused mutations outside the nucleoside analogue resistance sites. For the in vivo study, 14 patients with HBV-related end-stage liver disease re-infected after liver transplantation, and 20 cases without HBV re-infection as controls, were studied. Seventy-five percent of re-infected recipients showed multi-loci amino acid mutations at different sites besides lamivudine (LAM)-resistant loci in the P region, including in the glucocorticoid response element. Fifty percent of re-infected recipients had mutations in the "a" determinant region and flanking sequences. Re-infection was associated with negative serum hepatitis B immunoglobulin (HBIG), as measured by a microparticle capture enzyme immunoassay. Nucleotide mutations in the S region caused missense or synonymous mutations, which caused synonymous mutations in the overlapping P region. These results showed that effects of immunosuppressants on HBV genes in vitro were different from those in clinical recipients. Positive HBV DNA and gene mutations pre-transplantation were factors affecting re-infection post-transplantation. Multiple mutations found in the P and S genes suggest that the formation of quasispecies contributes to HBV re-infection after liver transplantation.


Assuntos
Produtos do Gene pol/genética , Genoma Viral , Antígenos de Superfície da Hepatite B/genética , Vírus da Hepatite B/genética , Hepatite B/imunologia , Imunossupressores/farmacologia , Transplante de Fígado , Adulto , Idoso , Sequência de Bases , Linhagem Celular Tumoral , Replicação do DNA/efeitos dos fármacos , Feminino , Variação Genética , Células Hep G2 , Humanos , Terapia de Imunossupressão , Masculino , Metilprednisolona/farmacologia , Pessoa de Meia-Idade , Mutação , Recidiva , Análise de Sequência de DNA , Tacrolimo/farmacologia
13.
Zhonghua Gan Zang Bing Za Zhi ; 20(1): 10-3, 2012 Jan.
Artigo em Chinês | MEDLINE | ID: mdl-22464698

RESUMO

OBJECTIVE: To analyze the prognosis of hepatitis B virus (HBV) recurrence after liver transplantation. METHODS: Thirty-eight patients (37 males; 1 female) with HBV-related end-stage liver disease underwent liver transplantation at our institute between December 1998 and November 2009 and experienced HBV recurrence. Clinical data from pre-transplant and follow-up examinations were retrospectively retrieved from medical records, and included serologic indices of HBV (HBV DNA, markers of liver function) and histological findings from liver biopsy. RESULTS: The median follow-up time was 45.1 months. The median time to HBV recurrence after transplantation was 31.8 months (range: 0.3 to 72.8 months) for histologically benign cases and 13.7 months (range: 0.3 to 66.6 months) for malignant cases. HBV DNA gene mutations were detected in 21% (8/38) of cases. Eighteen patients were treated with entecavir or adefovir, with respect to gene mutations, and HBV DNA fell below 103 copies/ml and liver function became normal. Twenty-two patients died, and causes of death included hepatocellular carcinoma (HCC, n=18), organ failure (n=2), or infection (n=1). CONCLUSION: HBV gene mutations and HCC recurrence were important risk factors for HBV recurrence in our study population. In addition, patients with benign liver diseases who received salvage therapy with adefovir or entecavir achieved a satisfactory prognosis.


Assuntos
Vírus da Hepatite B/genética , Hepatite B/virologia , Transplante de Fígado/efeitos adversos , Adenina/análogos & derivados , Adenina/farmacologia , Adulto , Feminino , Hepatite B/diagnóstico , Vírus da Hepatite B/efeitos dos fármacos , Humanos , Lamivudina/farmacologia , Masculino , Pessoa de Meia-Idade , Organofosfonatos/farmacologia , Prognóstico , Recidiva , Estudos Retrospectivos
14.
Hepatogastroenterology ; 59(115): 858-62, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22389257

RESUMO

BACKGROUND/AIMS: The increasing demand for transplantation has led application of steatotic liver as the graft. The aim of this study was to determine the effect of donor graft steatosis on overall outcome and tumor recurrence after liver transplantation for hepatocellular carcinoma. METHODOLOGY: 131 patients that underwent liver transplantation for hepatocellular carcinoma between 2007 and 2008 were included. Donor steatosis was categorized as non-steatosis group (0%-10%, n=101) and steatosis group (>10%, n=30). The Kaplan-Meier method and Cox proportional hazard regression model was used for data analysis. RESULTS: Postoperative recipient survival rate was 81% and 66.6% at 1 and 3 years, respectively, for non-steatotic graft; 87.5% and 58.3% for mild steatosis; 83.3% and 41.7% for moderate to severe steatosis (p=0.303). Postoperative tumor recurrence rate was 15.8% and 28.7% at 1 and 3 years, respectively, for grafts with no steatosis; 8.3% and 20.8% for those with mild steatosis; 33.3% and 50% for those with moderate to severe steatosis, (p>0.05). CONCLUSIONS: Steatotic donor was not associated with a worse prognosis in early stage postoperative and mild fatty liver did not increase tumor recurrence risks. The moderate to severe status of fatty liver had some effect on tumor recurrence.


Assuntos
Carcinoma Hepatocelular/cirurgia , Seleção do Doador , Fígado Gorduroso/complicações , Neoplasias Hepáticas/cirurgia , Transplante de Fígado , Recidiva Local de Neoplasia , Doadores de Tecidos/provisão & distribuição , Adulto , Carcinoma Hepatocelular/mortalidade , Distribuição de Qui-Quadrado , China , Fígado Gorduroso/diagnóstico , Feminino , Humanos , Estimativa de Kaplan-Meier , Neoplasias Hepáticas/mortalidade , Transplante de Fígado/efeitos adversos , Transplante de Fígado/mortalidade , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Hepatopatia Gordurosa não Alcoólica , Modelos de Riscos Proporcionais , Sistema de Registros , Medição de Risco , Fatores de Risco , Índice de Gravidade de Doença , Taxa de Sobrevida , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
15.
Hepatol Res ; 42(3): 280-7, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22176205

RESUMO

AIM: The aim of this study is to identify the titres of protective hepatitis B surface antibodies (anti-HBs) in the blood and their effective factors in the early stage after liver transplantation (LT) for hepatitis B virus (HBV) related diseases. The condition of anti-HBs lost in ascites fluid was also investigated. METHODS: Twenty-six patients who received LT were administered prophylaxis of lamivudine combining intravenous hepatitis B immunoglobulin (HBIG) post-LT. The titres of anti-HBs were recorded and analyzed daily in blood and ascites fluid within the first week post-LT. RESULTS: In the first 5 days post-LT, the titres of anti-HBs in HBV DNA positive groups, high hepatitis B surface antigen (HBsAg) groups, hepatitis B e antigen (HBeAg) positive groups were lower than that in the parallel HBV DNA negative groups, low HBsAg groups and HBeAg negative groups. The mean titre level of anti-HBs in ascites fluid is 224.89 IU/L and fluctuated from 0.00 IU/L to 968.50 IU/L, which is also correlated with anti-HBs titres in blood drawn at the same time (r = 0.927, P = 0.000). The level of anit-HBs in ascites fluid was very high; however, it fluctuated in a wide range (from 0.00 IU to 908.55 IU). CONCLUSIONS: Patients in high risk groups should receive a higher level of HBIG to maintain sufficient amounts of anti-HBs in the early stage post-LT, while the patients in low risk groups need a lower level of HBIG administration. Furthermore, the lost amount of anti-HBs in ascitic fluid post-LT has minimum impact on the anti-HBs titres in blood.

16.
Liver Transpl ; 16(12): 1440-2, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21117256

RESUMO

Use of livers infected with Clonorchis sinensis as donor organs for transplantation is controversial because of the potential associated risks. The low availability of donor livers at Tianjin First Center Hospital since 2003 prompted us to undertake cadaveric liver transplantation in 14 patients using donor livers infected with C. sinensis. None of the donors had been diagnosed with liver fluke infection before organ procurement, and in none of them was there laboratory evidence of abnormal liver function. After livers had been harvested and preserved, dead liver flukes were found in the bile of each donor; subsequent pathological examination of the flukes confirmed the diagnosis of clonorchiasis. Conventional orthotopic liver transplantation, with insertion of a T- tube, was undertaken in all 14 patients. Praziquantel, 25 mg/kg three times daily for two days, was administrated to the recipients starting on postoperative day 2. Results of tests of liver function improved rapidly after the operation in all of the patients. The median duration of follow-up was 31 months. The 1- and 3-year survival rates of the grafts were 85.7% and 78.6%, respectively. Postoperative biliary complications occurred in 2 patients (14.3%). No ova were detected in the bile or feces of any of the patients postoperatively. These findings suggest that livers infested with C. sinensis can be used as donor organs for liver transplantation. Further studies are required to establish definitive criteria for determining whether such donor organs may be used in a liver transplantation program.


Assuntos
Clonorchis sinensis/isolamento & purificação , Hepatopatias/cirurgia , Transplante de Fígado/mortalidade , Fígado/parasitologia , Adulto , Animais , Anti-Helmínticos/uso terapêutico , Clonorquíase/complicações , Clonorquíase/tratamento farmacológico , Estudos de Viabilidade , Feminino , Seguimentos , Rejeição de Enxerto/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Praziquantel/uso terapêutico , Fatores de Risco , Taxa de Sobrevida , Resultado do Tratamento
18.
Zhonghua Wai Ke Za Zhi ; 47(11): 818-20, 2009 Jun 01.
Artigo em Chinês | MEDLINE | ID: mdl-19961010

RESUMO

OBJECTIVE: To summarize the clinical feature of splenic artery aneurysms (SAA) in OLT recipient, and review the experience in diagnosis and management. METHODS: The clinical data, results of four-phase CT scanning and CT angiography of 450 recipients, who underwent OLT from December 2001 to December 2003 were analyzed statistically. RESULTS: Twenty of 450 recipients were diagnosed as SAA, the incidence was about 4.4%. Nineteen of them were diagnosed by four-phase CT scanning. Fifteen patients did not receive any treatment for SAA during OLT, but two of them suffered SAA rupture after OLT, among which one died of hemorrhagic shock although emergency operations were performed. The five patients, who were performed splenectomy with SAA resection during transplantation, recovered successfully after OLT, and their grafts' function was satisfactory. CONCLUSIONS: Morbidity of SAA is higher in patients of liver cirrhosis. Four-phase CT scanning can diagnose SAA exactly. In the early period post-OLT, SAA rupture happens frequently, so SAA resection should be performed during transplantation.


Assuntos
Aneurisma/diagnóstico por imagem , Aneurisma/cirurgia , Transplante de Fígado , Artéria Esplênica , Adolescente , Adulto , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Radiografia , Estudos Retrospectivos , Ruptura Espontânea/cirurgia , Resultado do Tratamento , Adulto Jovem
19.
Zhonghua Wai Ke Za Zhi ; 47(22): 1681-4, 2009 Nov 15.
Artigo em Chinês | MEDLINE | ID: mdl-20137715

RESUMO

OBJECTIVE: To discuss the technical improvement of the conventional thrombectomy for portal vein thrombosis (PVT) on liver transplantation. METHODS: The clinical data of 198 cases of liver transplantation with PVT who admitted in Tianjin First Central Hospital were analyzed retrospectively. According to the different treatments for PVT, these cases were divided into group A and group B. The conventional eversion embolectomy were performed in group A (n = 43) and the improved eversion embolectomy were performed in group B (n = 155). The general conditions, blood loss volumes, the achievement ratio of embolectomy, PVT recurrence rate and survival rate between the two groups were compared. RESULTS: No statistical significance on operation time between two groups (P > 0.05); the achievement ratio of embolectomy for Yerdel I-II were 100% in two groups, however, the achievement ratio of embolectomy for Yerdel III in group B was higher than that of group A (100% vs. 45.45%; chi(2) = 12.38, P < 0.01). Blood loss volumes in group B was significantly lower than that of group A [(4315.4 +/- 630.5) ml vs. (3509.2 +/- 862.7) ml, P < 0.05]. No statistical significance on Yerdel I and II PVT recurrence rate between two groups (P > 0.05). While thrombosis recurrent rate of Yerdel III PVT in group B was lower than that of group A(5.6% vs. 2/5; chi(2) = 4.09, P < 0.05). Perioperative mortality of Yerdel I-III patients were both 0 in two groups. 1-year survival rate of Yerdel I-III patients was similar in two groups (86.5% vs. 89.0%, P > 0.05). CONCLUSIONS: Improved eversion embolectomy can simplify the operation procedures, reduce blood loss, expand application range, increase the embolectomy success rate, decrease the PVT relapse rate.


Assuntos
Embolectomia/métodos , Transplante de Fígado , Veia Porta , Trombose Venosa/cirurgia , Adulto , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Veia Porta/cirurgia , Estudos Retrospectivos , Resultado do Tratamento
20.
Chin Med J (Engl) ; 121(20): 2001-3, 2008 Oct 20.
Artigo em Inglês | MEDLINE | ID: mdl-19080264

RESUMO

BACKGROUND: Although liver transplantation has become a standard therapy for end-stage liver diseases, the experience of pediatric liver transplantation is limited in China. In this article we report our experience in pediatric liver transplantation, and summarize its characters in their indications, surgical techniques, and postoperative managements. METHODS: Thirty-one children (< or = 18 years old) underwent liver transplantation in our centers. The mean age at transplantation was 12.4 years old (ranged from 5 months to 18 years) with 7 children being less than 4 years of age at transplantation. The most common diagnosis of patients who underwent liver transplantation were biliary atresia, Wilson's disease, primary biliary cirrhosis, glycogen storage disease, hepatoblastoma, urea cycle defects, fulminant hepatic failure, etc. The surgical procedures included 12 standard (without venovenous bypass), 6 pigyback, 6 reduced-size, 3 split, 3 living donor liver transplantation, and 1 Domino liver transplantation. The triple-drug (FK506, steroid, and mycophenolate mofetil) immunosuppressive regimen was used in most of patients. Patients were followed up for a mean of 21.8 months. RESULTS: Five of the 31 patients died during perioperative time; mortality rate was 16.1%. The reasons of death were infections, primary non-function, heart failure, and hypovolemic shock. Postoperative complications in 10 patients included biliary leakage, acute rejection, abdominal infection, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, and pulmonary infection. Overall patient cumulative survival rate at 1-, 3-, and 5-year was 78.1%, 62.6%, 62.6%, respectively. CONCLUSIONS: The most common indications of pediatric liver transplantation were congenital end-stage liver diseases. According to patients' age and body weight, standard, piggyback, reduced-size, split, or living donor liver transplantation should be performed. Pediatric liver transplantation especially requires higher surgical skills. The early postoperative management is the key to success. Postoperative bile leak was common, but most patients underwent liver transplantation had a better prognosis.


Assuntos
Transplante de Fígado , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Transplante de Fígado/efeitos adversos , Transplante de Fígado/mortalidade , Masculino , Complicações Pós-Operatórias/etiologia , Estudos Retrospectivos , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...